Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Green Pharmaceuticals Inc.
WARNING LETTER
•Green Pharmaceuticals Inc.•June 9, 2022

Green Pharmaceuticals Inc. – FDA Warning Letter, Jun 9, 2022

Record Details

The FDA issued a Warning Letter to Green Pharmaceuticals, an OTC human drug manufacturer, following laboratory testing of their SnoreStop NasoSpray, Homeopathic Anti-Snoring Nasal Spray. The product was found to be adulterated under section 501(a)(1) of the FD&C Act due to gross microbial contamination, with samples showing 420-6200 CFU/mL total aerobic microbial count and 30-3800 CFU/mL total yeast and mold counts, including *Providencia rettgeri*. This contamination is particularly concerning as the nasal spray is intended for use in children as young as five.

The firm's manufacturing methods, facilities, and controls were found to not conform to CGMP, rendering the product adulterated under section 501(a)(2)(B). Specifically, Green Pharmaceuticals failed to test finished drug products for objectionable microorganisms (21 CFR 211.165(b)), relying solely on their contract manufacturer's certificate of analysis for bulk product. The firm only began testing after FDA informed them of the contamination.

Furthermore, SnoreStop was identified as an unapproved new drug under section 505 of the FD&C Act, violating sections 301(d) and 505(a), as it is not generally recognized as safe and effective and lacks an FDA-approved application.

Green Pharmaceuticals conducted a voluntary recall of lot

Company
Green Pharmaceuticals Inc.
Inspection date
June 9, 2022
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations IV
People
  • Edith Scheiner
  • Steven E. Porter (Program Division Director)
View Company Profile

ID · 7557c3fb-bc65-4086-8b78-d9a6bf759a28

Violation Codes9
21 U.S.C. 351(a)(1)21 U.S.C. 35521 U.S.C. 33121 CFR 211.165(b)21 U.S.C. 321(g)(1)21 U.S.C. 321(p)21.U.S.C. 355(a)21 U.S.C. 331(d)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Green Pharmaceuticals Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.